Successful therapy of the prostaglandin defect "Wien-Hietzing" (lack of platelet high-affinity binding sites for prostaglandin I2).
Some years ago we detected a lack of platelet high-affinity PGI2 binding sites in a 10 year-old girl who presented to the outpatient unit with clinical symptoms and signs of acute popliteal artery occlusion. We named this new defect in the prostaglandin system "Wien-Hietzing". Acute surgery was successful. On the basis of earlier findings that aspirin is able to sensitize platelets to the action of PGI2 and produce beneficial changes in platelet sensitivity, we decided to treat this girl with a daily dosage of 20 mg aspirin orally. Repeated control examinations during the total follow-up period of about 6 years revealed normalized platelet sensitivity and normalized receptor behaviour. The girl is symptom-free to date. It is concluded that this prostaglandin defect may be successfully treated with long-term, low-dose aspirin administration.
Steurer
G
G
Department of Cardiology, University of Vienna, Austria.
Kaliman
J
J
Gludovacz
D
D
Sinzinger
H
H
D001157:Arterial Occlusive Diseases / Q000601:surgery; D001241:Aspirin / Q000627:therapeutic use*; D001792:Blood Platelets / Q000378:metabolism*; D002648:Child; D011464:Epoprostenol / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008661:Metabolism, Inborn Errors / Q000097:blood / Q000188:drug therapy*; D010974:Platelet Aggregation; D010976:Platelet Count; D011150:Popliteal Artery / Q000601:surgery; D044006:Receptors, Epoprostenol; D011982:Receptors, Prostaglandin / Q000378:metabolism*
D044006:Receptors, Epoprostenol; D011982:Receptors, Prostaglandin; D011464:Epoprostenol; D001241:Aspirin